Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This study suggests that IL-4 and IL-13 may play a role in the immunopathogenesis of alopecia areata in some patients, indicating a possible Th2-driven pathway in this condition.

This study found that skin bacteria promote regeneration in wound-induced hair follicle neogenesis, suggesting a role for IL-1β signaling and challenging the belief that infection inhibits healing.

This study found that ruxolitinib modulated inflammatory changes and stimulated growth factor signals by blocking the JAK-STAT pathway in an in vitro model of alopecia areata.

This study found that serum MIF levels were significantly higher in patients with extensive alopecia areata compared to those with mild alopecia areata and healthy individuals.

This study found that targeting IL-6, IL-1, and CCR6 signaling pathways may effectively reduce irradiation-induced alopecia and dermatitis in radiotherapy patients.

In this mini-review, recent insights suggest a possible role of type-2-related immunity in diseases like alopecia areata, vitiligo, and localized scleroderma, though whether this immune response benefits or worsens these conditions remains unclear.

This study found that EGFR inhibitors and ligands did not significantly affect the expression of inflammatory biomarkers in cultured sebocytes, except for a notable increase in IL-1 expression with EGF treatment.

This abstract discusses the role of advanced glycation end-products in aging-related skin damage, but does not provide new findings on their impact on alopecia.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This study suggests that IL-1β produced by dermal papilla cells, regulated by protein kinase C, may inhibit human hair follicle growth through paracrine signaling.

Tralokinumab may help improve symptoms of atopic dermatitis and alopecia areata.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

This article reviews the challenges in treating hidradenitis suppurativa and discusses potential treatment options, emphasizing the need for increased awareness and comprehensive care, but reports no new clinical results.

This study suggests that Cepharanthine, a monomer in traditional Chinese medicine, may help treat COVID-19 by affecting multiple signaling pathways, and that TNF and IL-17 inhibitors used in rheumatoid arthritis, ankylosing spondylitis, and gouty arthritis might also be beneficial.

This study found that compounds from *Tectona grandis* leaves showed moderate inhibition of steroid 5α-reductase, a factor in androgenetic alopecia, and exhibited anti-inflammatory properties by inhibiting nitric oxide and pro-inflammatory cytokines IL-1β and IL-6 in vitro, suggesting potential dual-action benefits for AGA management.

This review examines the interconnected processes of atopic dermatitis and alopecia areata, highlighting shared immune imbalances, genetic factors, and microbiome influences, while analyzing current and emerging treatments and identifying gaps in understanding these overlapping conditions.

This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.

In this case report, the authors described a 46-year-old woman with severe atopic dermatitis and alopecia areata, who experienced significant improvements in both conditions after treatment with the interleukin-13 blocker tralokinumab, suggesting a potential therapeutic role for targeting type 2 cytokine IL-13 in such cases.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

This review explores epidermolysis bullosa simplex subtypes caused by mutations in KRT5 or KRT14 and summarizes gene expression patterns and molecular mechanisms, without presenting new experimental results.

In this case report, the researchers observed that combining growth hormone therapy with the biologic drug dupilumab effectively improved growth and health outcomes in a patient with Netherton syndrome and comorbid hypopituitarism, suggesting a multidisciplinary approach may be beneficial for managing such cases.

This study found that molecular differences in paracrine factors between balding and non-balding hair follicles may enhance understanding of androgen action in hair disorders and potentially inform better treatments.

This study found IL-17/IL-36 signaling to be predominant in both endotypes of Netherton syndrome, with distinct molecular profiles between NS-ILC and NS-SE lesions, offering potential therapeutic targets.

This study found that human placenta hydrolysate effectively inhibited atopic dermatitis development in stimulated human cells and a mouse model, suggesting its potential as a therapeutic agent for related skin diseases.

This study found that a quinazoline derivative, SH-340, increased skin barrier-associated factors and inhibited TSLP expression and STAT6 phosphorylation in human primary keratinocytes, suggesting potential benefits for alleviating inflammation and improving skin barrier function in atopic dermatitis.

In this pilot study, the researchers observed that transplanting anagen hair follicles into human scars can promote remodeling of fibrotic tissue and inhibit pro-fibrotic factors, offering potential new treatments for mature scars.

This study reports that pumpkin seed oil-loaded niosomes significantly decreased hair loss and increased hair growth indicators in vivo, suggesting potential as a natural anti-hair loss therapy.

This study found that compounds isolated from Osmanthus fragrans var. aurantiacus demonstrated antioxidative and anti-inflammatory activities, potentially offering therapeutic benefits for inflammatory bowel diseases by inhibiting COX-2 and iNOS enzymes and blocking ERK 1/2 MAPK signaling.